Yao J K, Reddy R D, van Kammen D P
VA Pittsburgh Healthcare System, Pennsylvania 15206, USA.
Biol Psychiatry. 1999 Jun 1;45(11):1512-5. doi: 10.1016/s0006-3223(98)00184-x.
Previous studies have shown impaired antioxidant defense system in schizophrenia, including alterations in glutathione peroxidase (GSH-Px) activity in erythrocytes. There exists a related enzyme, human plasma GSH-Px (hpGSH-Px), that has not been previously examined in schizophrenia.
An enzyme-linked immunoassay was used to determine hpGSH-Px levels in male schizophrenic patients (n = 39), using a within-subject, on-off haloperidol (HD) treatment design, compared with age- and gender-matched normal control subjects (n = 37).
hpGSH-Px was not significantly different between normal control subjects and patients, consistent with our previous findings in erythrocyte GSH-Px. There were no significant treatment effects. hpGSH-Px was significantly and positively correlated with psychosis rating scores in patients both on and off HD treatment.
Although not different from normal controls, hpGSH-Px levels in patients may reflect oxidative stress associated with greater psychosis severity. The present findings thus suggest that schizophrenic patients, without obvious increase of endogenous antioxidant enzymes (e.g., hpGSH-Px), may be at risk for oxidative damage.
先前的研究表明精神分裂症患者的抗氧化防御系统受损，包括红细胞中谷胱甘肽过氧化物酶（GSH-Px）活性的改变。存在一种相关酶，即人血浆GSH-Px（hpGSH-Px），此前尚未在精神分裂症患者中进行过检测。
采用酶联免疫分析法，对39例男性精神分裂症患者进行自身对照的氟哌啶醇（HD）治疗前后hpGSH-Px水平测定，并与37例年龄、性别匹配的正常对照者进行比较。
正常对照者与患者之间的hpGSH-Px无显著差异，这与我们先前在红细胞GSH-Px方面的研究结果一致。未发现显著的治疗效果。HD治疗前后，患者的hpGSH-Px与精神病评定得分均呈显著正相关。
尽管患者的hpGSH-Px水平与正常对照者无差异，但可能反映了与更严重精神病相关的氧化应激。因此，目前的研究结果表明，精神分裂症患者在没有内源性抗氧化酶（如hpGSH-Px）明显增加的情况下，可能面临氧化损伤的风险。
